Walgreens has formed a Clinical Trials Patient Advisory Board to improve patient recruitment and retention in clinical trials.

BioAtla's Tab-cel demonstrated an overall response rate in heavily pretreated head and neck cancer patients, with 11 responses out of 29 evaluable patients.

RAPT Therapeutics reported a net loss of $30.5 million for Q1 2024, aligning with analyst estimates, while EPS was slightly better than expected at -$0.79.

Tyra Biosciences reported a widened net loss in Q4 2023 to $22.8 million, driven by increased research and development expenses.

Cofactor Genomics' OncoPrism test demonstrates a threefold increase in specificity over PD-L1 and a fourfold increase over TMB in predicting immunotherapy response.

Sagimet Biosciences is set to initiate two Phase 3 trials, FASCINATE-3 and FASCINIT, by the end of 2024 for non-cirrhotic MASH treatment.

Azitra dosed the first patient in its Phase 1b trial of ATR-12 for Netherton syndrome, a genetic skin disorder, marking a key milestone in the drug's development.

CoreMap has received FDA Investigational Device Exemption approval to extend its INvENI clinical study to the U.S., evaluating its proprietary electrophysiology mapping system in persistent atrial fibrillation patients.

Vir Biotechnology received FDA Fast Track designation for its combination therapy of Tibar and LPSN for Hepatitis Delta Virus (HDV), potentially accelerating its approval.

Senseonics Holdings reported a Q3 2024 revenue of $4.3 million, a decrease from $6.1 million in Q3 2023, impacted by inventory transition to Eversense 365.

Azitra dosed the first patient in its Phase 1b trial of ATR-12 for Netherton syndrome, a genetic skin disorder, marking a key milestone in the drug's development.

WELL Health and HEALWELL AI are expanding their strategic alliance to launch and manage clinical trial sites across WELL's Canadian clinic network.

IDEAYA Biosciences reports positive progress in multiple clinical programs, including darovasertib for uveal melanoma and IDE397 for MTAP-deletion cancers.

Jaguar Health's Q3 2024 net revenue increased by 11% compared to Q3 2023, driven by Mytesi sales and the launch of GelClear.

The FDA has accepted Satsuma Pharmaceuticals' 505(b)(2) NDA for STS101, a novel nasal powder formulation of dihydroergotamine mesylate (DHE) for acute migraine treatment.

Corbus Pharmaceuticals presented Phase 1 data for CRB-701, a Nectin-4 targeting antibody-drug conjugate, at the ASCO Genitourinary Cancers Symposium.

The FDA has cleared SystImmune's Investigational New Drug (IND) application for BL-M11D1, an antibody-drug conjugate (ADC), for relapsed/refractory Acute Myeloid Leukemia (AML).

SystImmune's BL-M17D1, an antibody-drug conjugate (ADC) with a novel linker and payload, has received FDA IND clearance.

SystImmune's BL-M17D1, an antibody-drug conjugate (ADC) with innovative linker and payload technology, has received FDA IND clearance for a Phase 1 clinical trial.

JCR Pharmaceuticals has completed the regulatory review by Japan's PMDA for a Phase I study of JR-441 in patients with mucopolysaccharidosis type IIIA (MPS IIIA).